Cleerly is a digital healthcare company that is transforming the approach to treating heart disease. With their clinically-proven, AI-based digital care platform, they provide personalized analysis and treatment of heart disease. Cleerly performs a non-invasive whole heart assessment to identify, characterize, and quantify plaque buildup, which is a key indicator of heart attack risk.

Their innovative technology works with coronary computed tomography angiography (CCTA) imaging to precisely identify and define atherosclerosis, enabling clinicians to develop tailored, life-saving treatment plans for all patients. What sets Cleerly apart is their focus on measuring atherosclerosis directly, rather than relying on indirect markers such as risk factors and symptoms. They offer a simpler, faster, and more accurate evaluation and reporting of heart disease, improving overall clinical and financial outcomes.

Cleerly's digital cardiovascular care management program provides physicians and patients with innovative tools to transform complex imaging data into actionable clinical insights. With their expertise and extensive clinical trials, Cleerly is revolutionizing the evaluation and management of coronary artery disease. Partnering with leading healthcare professionals and organizations, they are committed to providing a personalized approach to diagnosis, management, and treatment, backed by world-class clinical evidence